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Here, we investigated the biocompatibility of a bioactive sodium calcium silicate glass containing 2.6 
mol% Nb2O5 (denoted BGPN2.6) and compare the results with the archetypal 45S5 bioglass. The glass 
bioactivity was tested using a range of in vitro and in vivo experiments to assess its suitability for bone 
regeneration applications. In vitro studies consisted of assessing the cytocompatibility of the BGPN2.6 
glass with bone-marrow-derived mesenchymal stem cells (BM-MSCs). Systemic biocompatibility was 
verified by means of the quantification of biochemical markers and histopathology of liver, kidneys, 
and muscles. The glass genotoxicity was assessed using the micronucleus test. The regeneration of a 
calvarial defect was assessed using both qualitative and quantitative analysis of 3D microcomputed 
tomography images. The BGPN2.6 glass was not cytotoxic to BM-derived MSCs. It is systemically 
biocompatible causing no signs of damage to high metabolic and excretory organs such as the liver 
and kidneys. No mutagenic potential was observed in the micronucleus test. MicroCT images showed 
that BGPN2.6 was able to nearly fully regenerate a critical-sized calvarial defect and was far superior 
to standard 45S5 Bioglass®. Defects filled with BGPN2.6 glass showed over 90% coverage compare 
to just 66% for 45S5 Bioglass®. For one animal the defect was completely filled in 8 weeks. These 
results clearly show that Nb-containing bioactive glasses are a safe and effective biomaterial for bone 
replacement. 
 





Bone fractures are the most widespread large-organ traumatic injury that affects humans.1-2 
The regeneration process after fractures normally achieves a successful healing outcome, yet, up to 
10-15% of the patients show an impaired healing, delaying the process or even leading to a non-union.3 
Fractures represent not only a burden for the patient’s quality of life, but also the costs of surgery and 
hospitalization constitutes a considerable cost for socio-economic and health care systems.3 In fact, it 
has been reported that the treatment of an established non-union of a bone costs over $10,000 on 
average.3 The estimated number of fractures for the year 2000 was 9.0 million worldwide, but, as some 
fractures cause disability for a period longer than 1 year this number was estimated at approximately 
50 million.4 This high number of fractures stimulates the need to develop better synthetic materials for 
bone replacement. 
In 1971 Larry Hench developed the first bioactive material, the Bioglass® 45S5.5 This material 
is a glass composed of 46.1 mol. % SiO2, 24.4 mol.% Na2O, 26.9 mol.% CaO and 2.6 mol.% P2O5.
6-7 
Under physiological conditions the glass slowly dissolves releasing calcium and phosphorous ions into 
solution. These ions then precipitate to form an amorphous calcium phosphorous layer that then 
crystalizes to form a layer of hydroxyl carbonate apatite (Ca5(PO4)3OH) (HCA) on its surface.
8-9 Due 
to its micro-/nano-scale complexity this HCA layer supports the adsorption of adhesive proteins that 
will further anchor integrin proteins in osteogenic cells, which will allow the cells to attach, spread, 
and produce mineralized bone matrix whilst the biomaterial slowly dissolves, until it is completely 
substituted by the new-formed bone.5-6, 8, 10 Many variations of the original Bioglass® 45S5 
composition have been designed and investigated in the hope of improving the biological properties.7-
8, 11-12 
Incorporating niobium into biomaterials is of significant interest and has been reported to 
improve their mechanical and biological properties.12-23 Niobium has been incorporated into metallic 
alloys for dental implants where it imparts superior corrosion resistance, low cytotoxicity, and 
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enhanced wear resistance.21, 24 Furthermore, some investigations reported that sol-gel-derived niobium 
oxide gels promote apatite formation within a week of immersion in simulated body fluid which 
indicates that this element is a good candidate for bioactive glass for bone replacement.25 Niobium has 
already been incorporated into calcium phosphate invert glasses15 and in fluorapatite glass-ceramics26 
showing great biocompatibility and also stimulating osteogenic differentiation of human mesenchymal 
stem cells (MSCs) and maturation of mouse osteoblast-like cells (MC3T3-E1 cell) by means of direct 
contactor through its ionic dissolution products. Nb doped glasses are also reported into increase 
vascularization.27 However, despite its great potential for biomedical applications niobium has rarely 
been incorporated in silicon-rich bioactive glass such as Bioglass® 45S5. In view of that, we altered 
that composition of the original Bioglass® 45S5 replacing P2O5 (2.6 mol %) with Nb2O5 and 
investigated the biocompatibility, genotoxicity and the potential for osteointegration of this new Nb-
containing glass. The biocompatibility of Nb-containing glass was tested using a series of in vitro and 
in vivo experiments. The in vitro experiments assessed the cytocompatibility of the Nb-doped glass 
with Normal Human Osteoblasts (NHOsts) by quantitative MTT analysis and qualitative Live/Dead 
assay. Systemic biocompatibility was verified by means of quantification of biochemical markers of 
hepatic (TGO, TGP, and GamaGT), renal (creatinine and urea), and cardiac damage (total CK). In 
addition, histological sections of liver and kidneys were examined for any sign cellular or tissue 
damage. The glass genotoxic potential was tested using the micronucleus test. The regeneration of a 5 
mm sized calvarial defect was examined by means of both qualitative and quantitative analysis of 3D 
microcomputed tomography images. 
 
Experimental Section 
Preparation of bioactive glasses and conditioned cell culture media. We tested a variation of melt-
quench derived Bioglass® 45S5, (SiO2)46.1(CaO)26.9(Na2O)24.4(P2O5)2.6. In this variation 2.6 mol% of 
P2O5 were replaced by 2.6 mol% of niobium pentoxide (Nb2O5), resulting the composition named 
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BGPN2.6. The glass was prepared by thoroughly mixing the precursors oxides SiO2 (Alfa Aesar, 
99.5%), CaCO3 (Alfa Aesar, 99.95-100.5%), Na2CO3 (Sigma-Aldrich, ≥ 99.5%), P2O5 (Sigma-
Aldrich, ≥99.5%), and Nb2O5 (Sigma-Aldrich, ≥ 99.99%). The batches were melted at 1400ºC for 90 
minutes in platinum crucibles. The melt was then poured into graphite mold which had been preheated 
to 370°C and annealed at 500 °C overnight before being allowed to cool slowly to room temperature. 
After cooling down the glasses were ground to powder. Particles with different sizes have different 
surface areas and therefore different ion release rates, therefore the particle size was standardized 
between 40 and 63 µm using a series of micro sieves. For experiments with the cells, glass-conditioned 
media was prepared. For this, powders of BGPN2.6 and 45S5 were added to cell culture medium 
(Osteoblast Growth Medium Bullet Kit, Lonza, Walkersville, MD) at a concentration of 10 mg∙mL, 
mixed for 24 hours, filtered using an ultrafine filter (0.22µm pore size) and left within the cell incubator 
for 4 hours (time necessary for pH buffering). In this case filtering the media was important not just 
for sterilization (bacteria and fungus are bigger than 0.22 µm so they cannot pass through the filter) 
but also to guarantee no glass particle would be in direct contact with the cells (as all particles were 
larger than 40 µm), thus only the glass extracts were present in the final cell culture media.    
Determining pH behavior of culture media containing bioactive glasses prior cell treatment. Cell 
culture medium has bicarbonate ions in its composition. These ions ultimately interact with CO2 in the 
cell incubator in order to maintain the pH of the medium in an ideal level for cells. Glass dissolution 
affects the pH of the medium, usually increasing it, and pH directly influences cell behaviour. It well 
known that the body responds to pH alterations much more efficiently than cell culture medium does, 
so the increase in pH caused by the presence of bioactive glasses may be rapidly buffered.28 In view 
of this, we studied the kinetics of media buffering in the cell incubator over time in order to determine 
how much time would be necessary to neutralize their pH before adding the cells. For this, 500 µL of 
each of the following media were added to each well of a 24-well plate, in duplicate: (a) Control 
medium (Osteoblast Growth Medium Bullet Kit (OGM), Lonza, Walkersville, MD), (b) Osteogenic 
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medium (OGM containing osteogenic supplements), (c) 45S5 (OGM containing 1% w/v of 45S5), (d) 
BGPN2.6 (OGM containing 1% w/v of BGPN2.6). The pH was measured prior to incubation and after 
increasing time intervals up to 72 hours using a pH meter (Accumet®, Fisher Scientific).  
Cell Culture. Normal Human Osteoblasts (NHOsts, Lonza, Walkersville, MD) were cultured in 
growth medium (Osteoblast Growth Medium Bullet Kit, Lonza, Walkersville, MD). Cell flasks were 
kept in incubator at 37ºC in an atmosphere of 5% of CO2. The culture medium was changed every 
other day. All procedures using osteoblasts were carried out following the manufacturer’s protocol.   
MTT assay. MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) is a soluble tetrazole 
salt that can be reduced to insoluble strongly pigmented purple formazan by the redox potential in 
active mammalian cells. 5,000 Normal Human Osteoblasts (NHOsts, Lonza, Walkersville, MD) were 
seeded in each well of  24-well plates containing 500 µL of osteoblast growth medium per well.  After 
24 hours the growth medium was replaced by the treatment media (conditioned with glass extracts and 
negative and positive controls). Cell culture media conditioned with 1% w/v of 45S5 and BGPN2.6 
were used to treat the cells for 72 hours. A positive control group of NHOsts was treated with osteoblast 
growth medium (Osteoblast Growth Medium Bullet Kit (OGM), Lonza, Walkersville, MD). A 
negative control group of cells was killed by incubation in Etoposide (Sigma-Aldrich). To quantify 
cell viability 10 µL of MTT (Invitrogen®) (stock solution at the concentration of 5mg∙mL) were added 
to each well (containing 100 µL of phenol red-free culture medium) incubating for 4 hours in the cell 
incubator at 37°C and 5% CO2. After the incubation time the formed formazan was solubilized with 
Dimethyl sulfoxide (DMSO) (Invitrogen®) incubating it for 10 minutes. The absorbance of the 
converted formazan was measured at the wavelength of 570 nm using a microplate spectrophotometer 
(Thermo Scientific™ Multiskan™ GO). This experiment was performed in duplicate. One-way 
ANOVA and the post hoc test Tukey were used to compare the means of the groups. 
Live/dead assay. For this assay 10,000 NHOsts were seeded per well in a 24-well plate and treated for 
72 h with conditioned media containing the dissolution products of 45S5 and BGPN2.6 glasses at a 
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concentration of 10 mg/mL. Cells treated with osteoblast growth medium (Lonza, Walkersville, MD) 
were used as a positive control whereas cells killed with Etoposide (Sigma-Aldrich) served as negative 
control. In this assay live cells are distinguished by ubiquitous intracellular esterase activity, which is 
determined by enzymatic conversion of the virtually non-fluorescent cell-permeant calcein AM to the 
intensely fluorescent calcein. Calcein is retained within live cell’s cytoplasm, producing an intense 
green fluorescence (~495nm).29 Ethidium Homodimer-1 (EthD-1) enters cells with damaged 
membranes and undergoes a 40-fold enhancement of fluorescence upon binding to nucleic acids, 
thereby producing a bright red fluorescence in dead cells (ex/em ~495 nm/~635 nm). EthD-1 is 
excluded by the intact plasma membrane of live cells.29 For this assay all procedures were carried out 
following the instructions of the manufacturer (ThermoFisher-Scientific®). Briefly, calcein-green at 
0.5 μM and EthD-1 at 0.5 μM were combined into one solution and used to treat NHOsts cells. 100 
μL of staining solution was added per well and left to incubate for 45 min at room temperature 
(protected from light). Cells were photographed using a fluorescent microscope at 100× magnification. 
This experiment was performed in duplicate. 
Animals. All experimental protocols were in accordance with the ethical principles for animal 
experimentation adopted by the Brazilian College of Animal Experimentation (COBEA) and were 
approved by the Committee for Ethics in Animal Use of the University of Campinas – 
CEUA/UNICAMP (Protocol Number: 3467-1). We used 72 adult rats (HanUnib: WH (Wistar), ZFV, 
Hannover, Germany, 1987) weighing between 350 and 460 g provided by the Central Bioterium of 
UNICAMP (CEMIB).  The rats were maintained in the Bioterium of the Department of Anatomy, in 
the Institute of Biology (IB), UNICAMP. They stayed in standard boxes in controlled environmental 
conditions (12 hours’ bright/dark cycles) with standard food and water. Table 1 shows the sample size 
of the experimental groups and subgroups.  
Surgical Procedure. Before the surgery, animals were weighed and transferred into individual boxes. 
A pre-anaesthetic dose of Tramadol (TRAMAL® - RETARD) (5mg∙kg) was applied 15 minutes 
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before the injection of anaesthetics. Animals were anaesthetized by means of an intraperitoneal 
injection of a mixture of Xilazin (Xilazin - Syntec) (0.3 mg∙kg) and ketamine hydrochloride (0.8 
mg∙kg). A prophylactic dose of 1 mg∙kg of Enrofloxacin (Biofloxacin - Biovet) was applied to prevent 
bacterial contamination. First, an incision was made starting at the nose bridge, and ending at the base 
of the skull, using a scalpel. The skin, subcutaneous tissue, temporal muscle, and the periosteum were 
pulled aside for complete exposure of the parietal bone. A 5 mm round full-thickness calvarial defect 
was then created in the parietal bone using a 5 mm-diameter tissue punch (Richter®). In the control 
group, the critical sized defect was left empty whereas in the other groups it was filled with the different 
glass compositions (45S5 or BGPN2.6) in powder form. The periosteum was sutured using a 6-0 Nylon 
non-absorbent monofilament (ETHILON®) and the skin was sutured using a 4-0 Nylon non-absorbent 
monofilament (ETHILON®). In the SHAM group the periosteum and skin were sutured without 
making the bone defect (Figure 1). The sample number of each group is depicted on table 1.  
Systemic Toxicity. The systemic compatibility of the two compositions of bioactive glasses (45S5 and 
BGPN2.6) was tested by pathological analysis of histological sections of rats’ liver and kidneys and 
also by comparing the blood serum concentration of biochemical markers of renal, hepatic, and 
muscular damage of the experimental groups with the SHAM group (group without fracture). For this, 
following the experimental time (14, 28 or 56 postoperative days) rats were euthanized and their blood, 
liver, and kidneys were collected. The sample size of each group is showed in table 1. The specimens 
of liver and kidneys were fixed with Bouin solution for 24 hours and embedded in paraplast (Sigma-
Aldrich®). All paraplast-embedded histological sections were stained using Hematoxilyn and Eosin 
and histopathologically examined under a light microscope. The quantification of biochemical 
toxicological markers from kidneys (Creatinine), liver (TGO, TGP) and muscles (Total Creatine 
Kinase - Total CK) was performed using enzymatic kits (Interkit®).The normality of the data was 
attested by the kolmogorov smirnov test (KS test) and the results of the different groups were then 
compared using One-way ANOVA test with Tukey post hoc test.  
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Micronucleus test. Micronucleus induction is a key characteristic of genotoxic compounds and the 
analysis of micronuclei formation, resulting from DNA strand breakage (clastogens) or interference 
with chromosome segregation (aneugens), is an important component of toxicology screening of new 
biomaterials. For this assay, we collected bone marrow from rat’s femur using a disposable syringe 
containing 1 mL of 0.9% saline at room temperature. The harvested bone marrow was transferred to a 
sterile tube, homogenized and centrifuged for 10 minutes at 900 rpm and part of its supernatant was 
discarded. The sediment was re-suspended in the remaining supernatant. One drop of this bone marrow 
suspension was placed on one extremity of a microscope slide. Using another glass slide a smear was 
made and left to dry at room temperature. The dry slides were fixed in 100% methanol for 10 minutes 
and dried at room temperature. Once fixed, the slides were stained with Giemsa diluted in Sorensen 
buffer (Na2HPO4 0,06 M e KH2PO4 0,06 M - pH 6,8), at the proportion of 1 mL of Giemsa for 20 mL 
of buffer solution for 10 minutes, washed with distilled water, and dried at room temperature. Entellan® 
was used to mount the histological slides for further analysis. For the calculation of the relative number 
of micronucleus 3000 erythrocytes were counted per animal in five animals per group (45S5, BGPN2.6 
and SHAM). The means of micronucleus were compared to the SHAM group using One-way ANOVA 
test with Tukey post hoc test. 
Computed Microtomography of rats’ calvaria. Immediately after the euthanasia, the calvarias were 
dissected and fixed with 10% buffered formaldehyde for 24 hours and kept in 70% ethanol up to the 
analysis. Prior to the microcomputed tomography scanning specimens were left to dry at room 
temperature for at least 60 minutes. We scanned 5 calvarias per group. Scanning was performed using 
SkyScan 1278 with 84.6 µm of pixel size, 53kV, 0.5 mm of Al filter and 0.18° of rotation. For the 
image reconstruction a correction of 10% of Beam Hardening was applied together with a ring artefact 
correction of 5 and Gaussian smoothing of zero. The amount of bone formed within the defect was 
calculated as a percentage of the total volume of a pre-determined volume of interest and normalized 
by the mean values of the SHAM group (which represented 100%). The amount of bone found in the 
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control group served as a blank that was subtracted from the other values. The sample size used for 
this experiment is detailed on table 1. 
 
Results 
pH behaviour in culture media containing bioactive glasses. It is known that pH is a variable that 
significantly affects cell behaviour. For the cell culture experiments we decided to remove this variable 
in order to investigate the precise role of the ionic products derived from glass dissolution. For this, 
we studied the kinetics of media buffering in the cell incubator over time to determine how long it 
would take to neutralize media’s pH.  
We observed that all glass compositions caused an increase in pH which can be attributed to 
the release of Ca2+ and Na+ ions from the glass into the cell medium as previously described.30 After 
24 hours mixing the different glass compositions in media at a concentration of 10 mg∙mL we 
measured their pH. The pH reached 10.27 in the medium conditioned with 45S5 and 9.46 in the group 
BGPN2.6 (Figure 2). No glass was added to the control group (growth medium) and osteogenic group 
(osteogenic medium) and their pHs were 7.77 and 8.22 respectively.  
Cell culture medium containing living cells tends to become acidic over time due to normal 
cell metabolism reactions. Chemical reactions related to HCO3
- present in the cell medium and the 
CO2
 present in the cell incubator are responsible for buffering the system maintaining medium’s pH 
around 7.4-8.2 which is suitable for living mammal cells. We observed that it takes 4 hours inside the 
incubator for the media’s pH to reach physiological levels (Figure 2). Thus, to exclude pH as a variable 
all media were left to buffer in cell incubator for 4 hours prior being used to treat cells. 
Viability of bone-marrow-derived MSCs. The survival of Normal Human Osteoblasts (NHOsts) 
within the different media over 72 hours was assessed using MTT and Live/Dead assay (Figure 3). It 
can be seen that none of the glass-conditioned media were cytotoxic to the cells. It proves that the 
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addition of niobium species did not compromise the cytocompatibility of 45S5 and that niobium can 
replace phosphorous pentoxide (P2O5) without damaging living bone cells. 
Systemic Biocompatibility: Biochemical Markers. In all groups the levels of TGO/AST, TGP/ALT 
were similar to those of the Control and SHAM groups (Figure 4, upper row). This result shows that 
the presence of the implants did not cause any kind of damage to the hepatic cells. Results of the levels 
of renal (Creatinine) and cardiac (Total CK) biochemical markers support the claim that these materials 
are biocompatible as none of them showed significant differences between the glass-treated rats and 
those from the control and SHAM groups (Figure 4, bottom row). 
Histopathology. Histological sections of liver and kidneys were stained with Haematoxylin and Eosin 
and were qualitatively analysed. We looked for any sign of tissue damage or cellular disturbance. A 
thorough examination of the organs confirmed the results for the biochemical markers. After 56 
postoperative days no organ showed any noticeable sign of damage (Figure 5). In the livers all 
hepatocytes presented normal morphology as did the hepatic parenchyma, showing no aggregates of 
connective tissue or the presence of any inflammatory cells which could represent a sign of toxicity 
(Figure 5, upper row, A-C). In the kidneys, their functional units, the glomerulus appeared normal as 
well as the proximal and distal convoluted tubules (Figure 5, bottom row, D-F). Just as in the liver, 
no sign of inflammation or tissue damage was observed in any group attesting the integrity of the 
kidneys and that none of the materials caused any harm to these organs. 
Mutagenic Potential. The carcinogenic risk of Nb-containing glass was tested by means of the 
micronucleus test which is a method to assess chromosomal damage in cells exposed to genotoxic 
agents. We counted 3000 erythrocytes per animal and compared the mean of each group with the 
SHAM group. The SHAM group exhibited, on average, 1.87 micronucleus per thousand of 
erythrocytes. No significant difference was observed between the experimental groups and the SHAM 
group (P=0.0863) (Figure 6). This result reveals that none of the glass compositions are genetically 
toxic and suggest they display no mutagenic potential. 
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MicroCTs of rat calvaria. The regeneration of a 5 mm calvarial defect was assessed by means of 
microcomputed tomography (microCT). This analysis is a powerful tool for the evaluation of bone 
tissue because it provides clear visualization of the 3D microarchitecture of the bone. In the present 
work the qualitative and quantitative microCT analysis of the rat`s calvarias were performed ex vivo. 
MicroCT images showed that the calvarial defect maintained its size even 56 days after surgery in the 
control group, proving that it was in fact a critical-sized defect. The treatment with 45S5, on average, 
filled 65.63% of the bone defect whereas BGPN2.6 filled 91.66% of the defect, on average. In one rat 
BGPN2.6 completely filled the defect (Figure 7). 
Discussion 
We performed both in vitro and in vivo analysis in order to verify the biological properties of 
Nb-containing bioactive glass. The glass showed excellent cytocompatibility with normal Human 
Osteoblasts (NHOsts) as demonstrated in the in vitro assay. In the in vivo experiments it did not 
compromise high metabolic and excretory organs such as the liver and kidneys throughout the eight 
week period tested. Through microcomputed tomography we observed that Nb-containing glass was 
capable of stimulating the regeneration of a 5-mm calvarial defect in 56 days.  
When implanted into the body a biomaterial for bone replacement must be compatible with its 
surrounding cells in order to enable efficient osteointegration. The biocompatibility of 45S5 Bioglass® 
dissolution products (Ca, Si, Na and P) has been described in various studies.5, 6, 8 Elemental analysis 
using Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) revealed that the ionic 
products of Niobium-containing glass are similar to those from 45S5, apart from trace amounts of Nb, 
thus, this material is not expected to be toxic to living cells.23 Previous reports demonstrated the 
cytocompatibity of other niobium doped biomaterials with different types of cells.13, 17, 31 Pure niobium 
discs were shown to be cytocompatible with mesenchymal stem cells derived from human bone 
marrow (HBMSCs) seeded and grown onto its surface up to 10 day.13 Cells adhered well to the surface 
of pure-niobium discs presenting a spread morphology which is an evidence that they were active.13 
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Mesenchymal stem cells were also observed to attach and proliferate well onto niobium-doped 
fluorapatite glass-ceramics. The dissolution products of Nb-doped glass-ceramic were also shown to 
stimulate greater osteogenic differentiation of HBMSCs when mixed with osteogenic medium.17 Pure 
metalic Nb also proved to be bioinert when implanted into rats for 4 weeks.31  
In addition to the analysis of the cytocompatibility of the materials, which is a good sign of 
non-toxicity, it is also important to take into account the fact that the implant will progressively 
dissolve in the body fluid. Part of its dissolution products and even microscopic particles may get into 
the blood stream and end up in high metabolic and excretory organs such as liver and kidneys which 
may be of concern. This is the first study in which organs have been verified to test the systemic 
behavior of Nb-doped bioactive glass to ensure that no damage was caused by its dissolution products 
after eight weeks of implantation (Figure 4 and Figure 5). The observed results are in accordance with 
an investigation in which Swiss male mice were treated with a single dose (1 mL) of 3 % niobium 
species diluted in phosphate-buffered saline (PBS), intraperitoneally. In this cited study rats 
hepatocytes showed some signs of degeneration between the third and seventh day after the 
intraperitoneal application. However, after 12 days all livers appeared to regenerate with cellular 
mitoses.32 In our investigation we did not observe any sign of degeneration nor regeneration at any of 
the studied time points. We believe that in the aforesaid investigation they might have provoked a mild 
hepatic degeneration due to the direct intraperitoneal injection of a much higher dose of niobium 
species (~30µg per rat) compared to the present study (~3.4 µg per rat). 
The assessment of the genotoxic potential of new biomaterials is imperative. In order to 
evaluate the genotoxicity of Nb-containing glass we performed micronuclei analysis. This is 
considered to be one of the gold-standard analyses for the recognition of the mutagenic potential of 
any treatment. In the present study 3,000 erythrocytes were taken into account per animal and the 
number of micronuclei found was compared to the SHAM group (group in which no fracture nor 
treatment was performed). Nb-glass showed no sign of genotoxicity demonstrating that, at least in this 
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particular dose, niobium is a safe material to be used in biomaterials (Figure 6). Other metallic ions 
have been shown to possess genotoxic effects. Vanadium, one of the components of the titanium alloy 
(Ti-6Al-4V), a well-recognized primary metallic biomaterial for orthopedic implants, can generate 
long-term health problems such as peripheral neuropathy, osteomalacia and Alzheimers disease.33 
Furthermore, lanthanum and nickel were shown to cause some degree of DNA damage.34-35 Therefore, 
Nb-containing glass appears to be a safe biomaterial that causes no cellular or DNA damage and is 
therefore a very interesting candidate for use in biomedical devices for bone replacement.  
The osteoestimulative capacity of Nb-containing glass was tested by treating critical-sized 
calvarial defect for up to eight weeks. A critical size defect is defined as “the smallest size tissue defect 
that will not completely heal over the natural lifetime of an animal”.36 For the rat calvarial defect, 8 
mm is generally accepted to be of critical size.37 Nevertheless, we chose to work with 5 mm size defect 
because it can be made in one rat’s parietal bone without crossing the sagittal suture. The sutures are 
nearly immovable fibrous joints that connect two or more bones. In the case of the sagittal suture it 
connects the two parietal bones. It is important to take into account the fact that fibrous joints (such as 
the sagittal suture) show a very different pattern of regeneration from flat bones (such as parietal 
bones). In view of this, we believe the occurrence of these two different rates of regeneration at the 
fracture site might constitute an extra variable that could confuse the interpretation of the results as the 
bioactive glass may interact with these two tissues in different ways. Furthermore, even though our 5 
mm size calvarial defect showed very low regeneration along eight weeks, in order to avoid any 
influence of such regeneration over the results, the mean value of the control group (empty defect) 
served as a blank that was subtracted from the means of all other groups during the quantification of 
bone formation using MicroCT images. 
The analysis of MicroCT images showed that treating circular calvarial defect with Nb-doped 
glass promoted greater bone regeneration over eight postoperative weeks revealing the great 
osteostimulative capacity of this glass (Figure 7). Our study is the first one to report osteostimulative 
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effects of Nb-containing bioactive glass using critical-sized calvarial defect. Two other studies 
investigated the osteintegrative properties of other types of Nb-containing biomaterials.13, 21 Wang at 
al. implanted Ti–Nb-Zr-Ta-Si alloy into rabbit’s femur to assess its mineral apposition rate and bone-
implant contact.21 The authors concluded that Ti-Nb-Zr-Ta-Si alloy showed significantly higher 
mineral apposition rate compared to CpTi implants after 4 postoperative weeks and showed no 
difference in bone-implant contact (BIC). They suggested that Ti–Nb–Zr–Ta–Si alloy had favorable 
biocompatibility and had an effect on the promotion of osteogenesis.21 Furthermore, Bartolomé and 
colleagues verified the biological tolerance of new zirconia/Nb biocermets implants in rabbit’s tibias. 
Their results demonstrated the effectiveness of osseointegration after six postoperative months as new 
bone was observed around the implants at retrieval date.13 Together these results indicate that the 
presence of niobium in the bulk of biomaterials seems to improve material’s biocompatibility and 
increase bioactive properties such as osteoconduction and osteostimulation.  
It is important to considerate that the calvarial defect serves as a model for intramembranous 
bone formation and thus may be less applicable to biomaterials or strategies for endochondral bone 
formation;37 thus, this result may be applicable mainly for large fractures in flat bones such as those of 
the skull, ribs, pelvis and some parts of the vertebras. 
 
Conclusion 
In summary we conclude that the Nb-containing glass BGPN2.6 is not cytotoxic to Human 
Osteoblasts. Its biocompatibility was confirmed by the results of the in vivo experiments showing that 
the material does not cause any harm to high metabolic and excretory organs such as liver and kidneys. 
Moreover, the Nb-containing glass does not show any genetic toxicity, therefore can be used without 
risk of mutagenicity. These results attest this glass composition is biocompatible and, up to the used 
concentration, can be implanted into the body without any harm. Microcomputed tomography 
demonstrated that Nb-containing glasses stimulated the regeneration of a large calvarial defect and the 
16 
 
results showed a 40% increase in defect repair compared to 45S5 bioglass. Taken together these results 
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Captions for Figures 
Figure 1. Development of a critical size calvarial defect in rat: (a) an incision was made starting at the 
nose bridge, and ending at the base of the skull, using a scalpel; (b) skin, subcutaneous tissue, temporal 
muscle, and the periosteum were pulled aside for complete exposure of the parietal bones; (c) 5 mm 
round full-thickness calvarial defect was created in the parietal bone with a 5 mm-diameter tissue 
punch (Richter®); (d) in the control group, the defect was left empty, in the other groups it was filled 
with different glass compositions (in powder form); (e) The periosteum was sutured using a 6-0 Nylon 
non-absorbent monofilament (ETHILON®). (f) The skin was sutured using a 4-0 Nylon non-absorbent 
monofilament (ETHILON®). In the SHAM group the periosteum and skin were sutured immediately 
after step “(b)”, without making the bone defect.  
 
Figure 2. pH variation of different culture media along 8 h of incubation at 37 ºC and 5% CO2. It takes 
4 hours inside the cell incubator for the media’s pH to reach physiological levels (7.4 - 8.2). 
 
Figure 3. Live/Dead assay photomicroscopies of normal human osteoblasts (NHOsts) treated with 
Control medium (A), 45S5 (B), BGPN2.6 (C), and ETOPOSIDE (D) for 72 hours (100x 
magnification). Living cells appear in bright green whereas the dead cells appear in red. None of the 
glass conditioned media was cytotoxic to the human osteoblasts (E). Quantification of MTT assay 
displaying the absorbance as % of the control group and standard deviation of the mean (SEM) (E). 
One-way ANOVA revealed no significant difference between the groups treated with glass- 
conditioned media and the control group (ns bars). All groups showed significantly higher viability 
than the negative control group (ETOPOSIDE) (*).  
 
Figure 4. Blood serum concentration of biochemical markers of hepatic, renal and muscular damage 
after 56 postoperative days. Data are displayed as mean and SEM. One-way ANOVA and Tukey’s 
post-test were performed to compare the experimental groups (45S5 and BGPN2.6) with the SHAM 
group. No significant difference was found between treatment groups and SHAM group. This result 
reveals that none of the glass compositions were toxic to these three organs. 
 
Figure 5. Photomicrographs of histological sections of liver (upper row) and kidneys (lower row) after 
56 postoperative days. Control (A and D), 45S5 (B and E), and BGPN2.6 (C and F). Magnification 
200x. Haematoxylin and Eosin staining. No sign of damage was observed in any of the analyzed 
organs. None of the glass compositions were toxic to these organs in the studied experimental time. 
 
Figure 6. Number of micronuclei per 3000 erythrocytes. Data are displayed as mean and SEM. One- 
way ANOVA and Tukey’s post-test were performed to compare the experimental groups (45S5 and 
BGPN2.6) with SHAM. No significant difference was found between the experimental groups and the 
SHAM group (p=0.0863). This result shows that none of the glass compositions possesses mutagenic 
potential. The red arrow points to one micronucleus. 
 
Figure 7. 3D reconstructions of microcomputed tomography images of rats’ calvarias from the three 
experimental groups: Control (A-B), 45S5 (C-D), and BGPN2.6 (E-F). Images taken after 56 
postoperative days using SkyScan 1278. Almost no bone formation can be observed in the control 
group (A) after 56 days which confirms the model of a critical-sized defect. The group treated with 
45S5 (C) showed a good amount of bone within the defect yet not enough to completely fill it. The 
composition BGPN2.6 (C) was the only one that was able to completely fill the 5 mm calvarial defect 
after 56 days in one of the subjects. 
 
Table 1. Sample division into the different experimental groups  
 Number of rats 
Material 14 days 28 days 56 days 
Control 6 6 6 
Sham 6 6 6 
45S5 6 6 6 
BGPN2.6 6 6 6 
   Total:                                                                                                              72 rats 
 
 







